TMED3 and hepatocellular carcinoma: For instance, Sakabe T et al. reported that DKK1 might be an unfavourable prognostic marker for HCC patients [11]; Zheng H et al. found that TMED3 promotes HCC progression [12]; and Emma MR et al. identified NUPR1 as a promising target in HCC for its effects in controlling cell growth, migration, invasion and sorafenib resistance [13].